HE4 tumor marker concentration in neoplastic peritoneal effusion and in peritoneal fluid associated with benign gynecological diseases by Anita Chudecka-Głaz et al.
Chudecka-Głaz et al. Journal of Ovarian Research 2014, 7:22
http://www.ovarianresearch.com/content/7/1/22RESEARCH Open AccessHE4 tumor marker concentration in neoplastic
peritoneal effusion and in peritoneal fluid
associated with benign gynecological diseases
Anita Chudecka-Głaz1*, Aneta Cymbaluk-Płoska1, Janusz Menkiszak1, Agnieszka Sompolska-Rzechuła2,
Elżbieta Byra3 and Izabella Rzepka-Górska1Abstract
Background: The aim of our study was to evaluate the behaviour of the human epididymis protein 4 (HE4) in the
peritoneal fluid encountered in various female genital diseases.
Methods: We enrolled 139 patients, 40 with ovarian cancer (group I), 82 with benign diseases (group II), and 17
with other malignant neoplasms (group III). The HE4 tumor marker concentrations were determined in serum, in
the peritoneal effusion and ovarian cyst/ tumor fluids, CA125 in the serum only. We compared the groups,
examined correlations and determined corresponding ROC curves. We evaluated the relationship between the HE4
marker concentration in the peritoneal effusion in the group I, depending on the selected prognostic parameters.
Results: The HE4 median value between the study groups did not differ statistically significantly and were as
follows: in group I 3322 pmol/L, in the group II 2150 pmol/L and in the group III 627 pmol/L (p = 0.206376 for the
groups I and II, p = 0.05929 for the groups I and III and p = 0.0797 for the groups II and III. In group I there were no
differences found in the HE4 concentrations in the peritoneal fluid, depending on the stage, grade, the presence of
neoplastic cells and the peritoneal dissemination.
Conclusions: The HE4 marker concentrations in the peritoneal fluid are highly irrespective of the pathology
observed in the female sexual organ. Therefore, it seems that its determinations in the peritoneal fluid are
completely useless in terms of diagnostics. More research is needed on the role of the HE4 marker, especially the
place of its formation and possible use in the targeted therapy.
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The ovarian cancer is a new growth tumor whose statis-
tics on mortality are poor despite using more and more
effective and sophisticated diagnostic methods, as well
as more and more novel methods of treatment. This is
caused by the fact that ovarian cancer is a tumor charac-
terized by rapid growth, by a specific peritoneal way of
dissemination in an early stage of disease, which results
in ascites formation [1]. Neoplastic peritoneal effusion is
research material of high importance. It is associated* Correspondence: anitagl@poczta.onet.pl
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article, unless otherwise stated.with searching for the diagnostic usefulness of peritoneal
effusion as well as with the desire to acquire detailed
knowledge of all its physiopathological aspects, which
could give rise to increasingly popular and more specific
methods of intraperitoneal treatment [2-4].
There are many works on the behaviour of the
markers, cytokines, and other substances in peritoneal
effusion [5-8]. However, so far only one publication has
appeared, devoted, to a negligible extent, to the re-
search on the human epididymis protein 4 (HE4)
marker in the neoplastic ovarian peritoneal effusion [9].
The HE4 overexpression in the ovarian cancer cells was
demonstrated in the late nineties [10], and in 2003 in
the Hellstrom studies [11] it was demonstrated as a
tumor marker for ovarian cancer. At present, the HE4Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this





Epithelial ovarian cancer patients 62,35 40
o Serous 63,9 31
o Endometrioid 60,66 6
o Mucinous 49,66 3
FIGO I, II 53.3 10
FIGO III, IV 65.37 30
Grading 1 52 7
Grading 2 63.4 9




o Functional cysts 45,14 21
o Ovarian endometrioma 35,71 14
o Mature teratoma 28 9
o Borderline epithelial tumors 41,78 9
o Benign epithelial and gonadal tumors 50,69 16
o Myoma 42,4 5
o Inflammation 37,5 4
o Cirrhosis 47,75 4
Other malignant neoplasms 56,24 17
o Lymphoma 41 1
o Malignant GCT 65,5 2
o Breast cancer 56 4
o Cervical cancer 43,6 3
o Endometrial cancer 61,3 3
o Stomach cancer 61,5 4
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well as prognostic significance [16-19]. However, its
exact biological significance, or its possible involvement
in the carcinogenesis process of ovarian cancer is not
yet known.
The aim of our study was to evaluate the behaviour
of the HE4 glycoprotein in the peritoneal effusion of
patients with ovarian cancer and in other gynecological
and non-gynecological diseases, as well as to assess its
diagnostic usefulness.
Materials and methods
139 women treated at the specialist cancer centre in
2012–2013 were enrolled in the study. The patients
at the time of reporting to the Department signed in-
formed consent for the study within the research pro-
ject approved by the Commission of Bioethics of the
Pomeranian Medical University. Patients who had indi-
cations for surgery were qualified as eligible for the
study: i.e. patients with suspected ovarian cancer, other
non-ovarian neoplasms, and patients with potentially
benign gynecological diseases. The day before the sched-
uled surgery blood samples were taken and the CA125
and HE4 concentrations determined. Finally, those pa-
tients were qualified for the study, in whom during surgi-
cal treatment the peritoneal effusion and/or fluid from
the ovarian tumor/cyst was available. Examination of the
HE4 marker was carried out on the date of the fluid
sample collection without having to freeze the collected
material.
Following the outcome of the histopathological examin-
ation, the patients were divided into 3 groups (Table 1):
1. Group I - patients with ovarian cancer, n = 40
2. Group II-patients with gynecological and non-
gynecological benign diseases, n = 82
3. Group III-patients with other malignant neoplasms,
n = 17
The median HE4 marker concentration in the periton-
eal fluid and in the serum as well as that from serum
CA125 were compared between the groups and sub-
groups. Additionally, the correlations between the tested
markers in the serum and in the tested fluids were
examined. In the ovarian cancer group the values of the
studied markers were also analysed and compared, de-
pending on the selected prognostic factors: stage, grade,
presence of neoplastic peritoneal dissemination and
presence or absence of neoplastic cells in the fluid. The
diagnostic usefulness of the HE4 determinations in the
fluid and serum, and of CA125 in serum was evaluated
by determining the ROC curves. In a small number of
patients the behaviour of HE4 in the fluid from the ovar-
ian tumor/cyst was examined.Marker analysis
Assays were performed at the Central Laboratory of the
Independent Public Hospital.
CA125 was determined with the Architect i2000
assay from Abbott Diagnostics. The normal range was
1–35 U/ml.
The serum, peritoneal and cyst/tumor fluid HE4 concen-
trations were measured with the Elecsys ECLIA assay from
Roche running on the cobas e 601 analyser. The measure-
ment range was 15.0-1500 pmol/L. Samples exceeding the
upper range were diluted with Elecsys Diluent Multiassay.
The manufacturer’s instructions were followed and control
samples were within the normal range. The normal upper
limit range for serum was below 70 pmol/L.
Statistical analysis
The statistical analysis was performed using STATISTICA 9.1
PL program
The entire group was analysed to check the normal dis-
tribution using the Shapiro-Wilk test. Due to the fact
Table 2 HE4 concentrations in serum, peritoneal fluid and tumor/cyst fluid and CA125 concentrations in serum in
examined groups
HE4-peritoneal fluid [pmol/L] HE4- serum [pmol/L] CA125- serum [mIU/ml] HE4 –tumor/cyst fluid [pmol/L]
Group I 3322 452.05 885.45 9162
[median/95% CI] [10.78-6633.22] [−272.37-1176.47] [−732.04-2502.94] [9157.69-9166.3]
Group II 2150 53.25 33.250 2694
[median/95% CI] [−1334.88-5634.88] [28.46-78.04] [−8.01-74.51] [−1902.9-7290.9]
p value 0.206376 0.0000001 0.0000001 -
Group I 3322 452.05 885.45 9162
[median/95% CI] [10.78-6633.22] [−272-1176.47] [−732.04-2502.94] [9157.69-9166.3]
Group III 627.4 87.6 231.6 10522
[median/95% CI] [−132.1-1386.9] [17.63-157.57] [−191.76-654.96] -
p value 0.05929 0.001652 0.010584 -
Group II 2150 53.25 33.250 2694
[median/95% CI] [−1334.88-5634.88] [28.46-78.04] [−8.01-74.51] [−1902.9-7290.9]
Group III 627.4 87.6 231.6 10522
[median/95% CI] [−132.1-1386.9] [17.63-157.57] [−191.76-654.96] -
















































Figure 2 Scatterplot of serum HE4 and serum CA 125
concentrations in groups I (ovarian cancer), II (gynaecological



























































Figure 1 Scatterplot of HE4 concentrations in peritoneal fluid and
tumor/cyst fluid in groups I (ovarian cancer), II (gynaecological
and non gynaecological benign diseases) and III (other
malignant neoplasms).
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parametric U Mann–Whitney test was used to compare
median values between the groups and determined con-
fidence intervals. The scatter plots of the HE4 marker
empirical points in serum, in peritoneal fluid, and in the
fluid from the cyst/tumor as well as for CA125 in serum
for the analysed groups I, II and III were created.
Because of the poor legibility of the scatter plots of the
actual values, which is related to the fact that these
characteristics do not have normal distribution, values
transformation was used by means of radix 2 (log2)
logarithm. The resulting diagrams allowed the clear repre-
sentation of the logarithm values scatter.
In order to determine the strength of the relationship
between the analysed markers the Spearman’s rank cor-
relation coefficient was used. Selected results of this ana-
lysis were presented in the form of diagrams.
The receiver operating characteristic (ROC) curves
were obtained and the area under curve (AUC) was cal-
culated with 95% confidence intervals according to the
nonparametric method of DeLong [20]. We also used
this method to compare the AUCs. The level of signifi-
cance was taken as p < 0.05.
Results
Comparisons of the groups and subgroups
The patients characteristics are shown in Table 1. The
serum marker determination was carried out in 139 pa-
tients. The peritoneal effusion was collected from 119
patients. The fluid samples from the ovarian tumor /cystTable 3 HE4 concentrations in serum, peritoneal fluid and tum
examined subgroups of group II
HE4-peritoneal fluid [pmol/L] HE4- serum [pm
Functional cysts 1799 52.6
[median/95% CI] [−1152.67-4750.66] [19.53-85.67]
Endometrial cysts 5248 45.05
[median/95% CI] [−2563.74-13059.74] [31.66-58.44]
Mature teratoma 405.3 47.65
[median/95% CI] [3.13-807.47] [30.86-64.44]
Borderline tumors 4772 84.3
[median/95% CI] [−2551.87-12095.87] [30.34-138.26
Benign epithelial 2150 56.850
/gonadal tumors [−5878.85-10178.85] [43.64-70.07]
[median/95% CI]
Myomas 4822 58.3
[median/95% CI] [−2435-12079.64] [36.79-79.81]
Inflammation 498.6 65.7
[median/95% CI] [−573.25-1570-45] [57.09-74.31]
Cirrhosis 675.95 112.6
[median/95% CI] [−113.78-1465.68] [28.17-196.83were collected from 27 women. Median HE4 values in
the peritoneal fluid, in the tumor/cyst fluid and serum
and median serum CA125 values are presented in
Table 2 and the logarithmized values of markers are
shown on Figures 1 and 2. No statistically significant dif-
ferences were found for HE4 marker in the peritoneal
fluid between the groups. No comparison was made be-
tween the groups concerning HE4 in tumor/cyst fluids
due to small number of cases.
There were no statistical differences found in group I, de-
pending on the histopathological type of the HE4 values in
the peritoneal fluid and serum. Due to the small number of
cases of mucinous and endometrioid carcinomas the statis-
tical analysis was only performed between the subgroup
serous vs mucinous + endometrioid, p = 0.4532 (for the
peritoneal fluid) and p = 0.2499 (for the blood serum). The
following median values and 95% confidence interval of
HE4 in peritoneal fluid were found in serous 4087 (60.18-
8113.82) pmol/L, endometrioid 3664 (−2128.47-5817.67)
pmol/L and mucinous carcinomas 1844.6 (−323.65-
8683.65) pmol /L .
The median values of HE4 in the peritoneal fluids,
the tumor/cyst fluids and in serum of CA125 and
HE4 in the subgroups of the group II are presented
in Table 3. In inflammatory conditions, myomas and
for cirrhosis, only peritoneal fluid and serum were
analysed. No median values were compared within
the subgroup of myomas, hepatic cirrhosis and
inflammations due to the small number of cases. In
other subgroups of the group II the significantor/cyst fluid and CA125 concentrations in serum in

























































































Figure 3 Spearman’s correlations between the HE4 concentration in serum and the HE4 concentration in the peritoneal fluid in group I,
II, and in all examined patients.
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found between the functional cysts and teratomas,
(p = 0.0391), borderline malignancy tumors and terato-
mas, (p = 0.008), myomas and teratomas (p = 0.0225)
and between the endometrial cysts and teratomas,
(p = 0.0217).Linear correlations
Assessment was made, whether there is a relationship
between the tested markers using the Spearman’s rank
correlation coefficient. No significant correlation was
found between HE4 in serum and HE4 in the peri-
toneal fluid; the HE4 serum versus the HE4 tumor/
cyst fluid; the CA125 serum and the HE4 tumor/cyst
fluid and the CA125 serum versus HE4 in peritoneal
fluid when conducting the analysis of the total stud-
ied patient. The only positive significant relationship
was found between serum levels of CA125 and serum
levels of HE4 (rs = 0.6678, p = 0.000001). When analys-
ing the particular groups, there was a statistically
significant, strong correlation between the HE4
marker concentration in the serum and its concentra-
tion in the peritoneal fluid in ovarian cancers group
(rs = 0.6909, p < 0.000001), Figure 3. In the groups II
and III no correlation was observed.Table 4 HE4 concentrations in serum and peritoneal fluid, CA
cancer (group I) according to FIGO stage, peritoneal carcinom
HE4-peritoneal fluid [pmol/L]
FIGO I, II 2306
[median/95% CI] [−945.89-5558.49]










Neoplastic cells in 4412
Peritoneal fluid YES [−211.66-9035.66]
[median/95% CI]
Neoplastic cells in 3236
Peritoneal fluid NO [353.69-6116.31]
[median/95% CI]
p value 0.3868Tested markers depending on the selected prognostic
factors
There were no statistically significant differences found in
the HE4 concentrations in the peritoneal fluid, depending
on the stage, grade, peritoneal dissemination and presence
or absence of neoplastic cells. The HE4 serum values dif-
fered significantly between low-advanced (FIGO I and II)
and high-advanced (FIGO III and IV) stages, high- and
low-differentiated tumors. There is no significant differ-
ence depending on presence or absence of peritoneal dis-
semination (Table 4). The median CA125 concentrations
in serum manifested a statistically significant difference
only depending on the grade (Table 5).ROC curves
The ROC curves were analysed for the investigated tumor
markers and the areas under the curve (AUC) were com-
pared. HE4 marker in serum had the highest diagnostic
value in this study - its AUC is 0.905, and CA125 AUC is
0.871. The AUC value for HE4 in the peritoneal fluid and
in the fluid from the tumor/cyst was equal to 0.575 and
0.638, respectively, (Figure 4). Statistically significant differ-
ences were found between AUC of HE4 from the periton-
eal fluid and serum, (p = 0.0001) and between the HE4
from peritoneal fluid and tumor fluid, (p = 0.0009).125 concentrations in serum in patients with ovarian
atosis and presence of neoplastic cells in peritoneal fluid
















Table 5 HE4 concentrations in serum and in peritoneal fluid, CA125 concentrations in serum, in patients with ovarian
cancer (group I) according to cancer grade
HE4-peritoneal fluid [pmol/L] HE4- serum [pmol/L] CA125- serum [mIU/ml]
Grade 1 1844.6 49.9 75
[median/95% CI] [−844.67-4533.87] [37.41-62.39] [−58.27-208.27]
Grade 2 4180 439.3 919.5
[median/95% CI] [−28.69-8388.69] [−452.11-1330.71] [−845.7-2684.7]
p value 0.1044 0.0093 0.0137
Grade 1 1844.6 49.9 75
[median/95% CI] [−844.67-4533.87] [37.41-62.39] [−58.27-208.27]
Grade 3 4444 548.35 1770.05
[median/95% CI] [263.07-8624.93] [−235.46-1332.16] [−757.23-4297.33]
p value 0.1337 0.0011 0.0019
Grade 2 4180 439.3 919.5
[median/95% CI] [−28.69-8388.69] [−452.11-1330.71] [−845.7-2684.7]
Grade 3 4444 548.35 1770.05
[median/95% CI] [263.07-8624.93] [−235.46-1332.16] [−757.23-4297.33]
p value 0.9608 0.7587 0.8154
Grade 1 and 2 2958 97.2 215.6
[median/95% CI] [48.29-5867.7] [−13.51-207.91] [−204.63-635.83]]
Grade 3 4444 548.35 1770.05
[median/95% CI] [263.07-8624.93] [−235.46-1332.16] [−757.23-4297.33]
p value 0.4141 0.0331 0.0375
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In cases of neoplastic dissemination, the ascites forma-
tion mechanism is complex. It is associated with the in-
creased tumor microvascular permeability, as well as
with the fact that the tumor itself is capable of its pro-
duction. The peritoneal fluid observed in the patients
with ovarian cancer is the subject of considerable re-
search in connection with great hopes for the creation of
the targeted intraperitoneal therapy [2]. For this to hap-
pen it is necessary to know the exact physiopathology of
that fluid.
The aim of our study was first of all to examine the
behavior of the HE4 marker concentrations in the peri-
toneal fluid of different origin, in the course of both
neoplastic diseases and benign illness.
The HE4 tumor marker has already been approved for
the diagnosis and monitoring of ovarian cancer [11-14].
We also know more and more about its prognostic sig-
nificance [16-19]. However, what has so far been estab-
lished in terms of its biological function in physiological
conditions and in ovarian cancer? A hypothesis was
advanced that the WFDC2 protein may be a component
of the innate immune response in the lung, nose and oral
cavity [21,22]. By immunohistochemical examination the
expression of HE4 was found in a normal epithelium of
the genital tract in women, i.e. endocervical, endometrialglands, fimbriae of fallopian tubes and in Bartholin's
glands. In neoplastic tumors the greatest expression was
found in serous ovarian cancer with varying grades of
malignancy (including borderline tumors), and the ma-
jority of endometrial and clear cell type. No expression
was found in the germ cell, gonadal tumors and mucinous
carcinomas [23]. Drapkin et al. [24] also demonstrated the
expression of WFDC2 glycoprotein in inclusion ovarian
cysts of the Mullerian origin ovarian cancer, pointing at
possible involvement of these lesions in the process of
ovarian carcinogenesis. The lack of changes in the HE4
concentrations in serum in the course of a woman’s men-
strual cycle indicates a lack of correlation with and depend-
ence on hormones of the menstrual cycle [25,26]. Data on
the role of HE4 in the carcinogenesis are inconsistent. Gao
et al. [27] demonstrated that the transfer of “exogenous
HE4 gene” to the ovarian cancer cell lines significantly pro-
motes cell apoptosis and it can contribute to the protective
role of this gene in the ovarian cancer progression process.
Quite different are the conclusions of the study conducted
by Zou et al. [28], who investigated nine cell lines. They
found out that the HE4 gene silencing results in cell div-
ision stopping in the G0/G1 phase which in turn is associ-
ated with the inhibition of proliferation, migration and
invasion of the ovarian cancer cells. The HE4 participation
in promoting the neoplastic tumor growth was also
305,6
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HE4 serum, AUC= 0.906 ; n=139 CA 125 serum, AUC=0.871; n=139
17906
2890
HE4 peritoneal fluid, AUC=0.575 ; n=119 HE4 tumor/cyst fluid, AUC=0.638 ; n=27
Figure 4 ROC curves for HE4 in serum, in peritoneal fluid and in tumor/cyst fluids and CA125 in serum of examined patients.
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onstrated that the HE4 expression in cancer cells is
associated with greater adhesion, migration and prolifera-
tion which may be dependent on the EGFR-MAPK cas-
cade. HE4 protein, in the opinion of the authors, should
be considered in the aspects of targeted therapy.
Until now two papers have been published in which
the HE4 marker concentration was examined in body
fluids apart from blood [9,31]. Eisammak et al. [31]
assessed HE4 concentrations in the transudative and ex-
udative pleural fluid of different origins. They found sta-
tistically higher HE4 concentrations in the exudative
neoplastic fluid (2878.5 pmol/L) compared to the pleural
fluid in benign lung diseases (transudate-305 pmol/L,
exudate-358.3 pmol/L). In addition, HE4 serum levels
correlated with the HE4 concentrations in the exudative
fluid. The area under the curve was even greater for
HE4 in the pleural fluid qualified as a good diagnostic
marker. The results presented by Braicu et al. [9] are most
similar to the results of our research because they exam-
ined HE4 concentrations in neoplastic peritoneal fluid. Butresults obtained in their study did not refer to diagnostic
value of HE4 and because of that the author did not
examine ascites in benign gynaecological conditions.
The mean value of HE4 in ovarian neoplastic peritoneal
fluid was equal to 4339 pmol/L (2117–7752 pmol/L), and
in our study, we obtained similar results of HE4 in peri-
toneal neoplastic effusion (mean 5024.19 pmol/L, range:
223–30000 pmol/L; median 3322 pmol/L, 95% CI 10.78-
6633.22). Similarly to our study, the authors found no
differences in mean values of HE4 in the peritoneal fluid
depending on the stage of ovarian cancer, and its differ-
entiation. The authors [9] showed that the HE4 concen-
tration is dependent on the amount of peritoneal fluid:
the greater the amount of the fluid, the greater concen-
trations were observed by the authors. In our research
we did not divide the group of tumors according to their
amount of peritoneal fluid, but in small liquid amounts
we detected quite often very high HE4 concentrations,
also in the benign diseases. Sometimes the HE4 values
exceed the concentrations found in malignant ascites.
According to the authors [9], the HE4 marker
Chudecka-Głaz et al. Journal of Ovarian Research 2014, 7:22 Page 9 of 10
http://www.ovarianresearch.com/content/7/1/22determined in peritoneal fluid also has a prognostic sig-
nificance and correlates with selected parameters of sur-
vival: with OS in univariate analysis (p = 0.044) and
platinum response (p = 0.023).
The results of our study are somewhat surprising. For
the first time we have examined HE4 concentrations in the
peritoneal ovarian neoplastic fluid, also in a variety of be-
nign diseases and other cancers, not only gynecological
ones. Although the median values differed between the
groups, we did not find any statistically significant differ-
ence between the investigated populations. The HE4 con-
centrations in the peritoneal fluid did not differ between
ascites in the course of the ovarian cancer, ascites of other
new growth tumors or in comparison with benign patho-
logical states such as uterine myomas, benign ovarian cysts
or inflammatory states, accompanied by the presence of
the peritoneal fluid. At this point a question arises, whether
HE4 tested in the peritoneal fluid is definitely produced by
the new growth tumor cells, as was suggested by other au-
thors. It appears that the high HE4 values observed in the
peritoneal fluid in case of benign diseases are inconsistent
with these established facts. The higher HE4 concentra-
tions in the peritoneal fluid, accompanied by peritoneal
dissemination or where cancer cells were present in the
fluid, are also statistically insignificant. The maximum
HE4 values, both in the peritoneal fluid and in the
fluids from the tumor/cyst were found in the patients
from group II but not in the ovarian cancer patients,
and they were as follows: 79610 pmol/L in the peri-
toneal fluid of patients with mucinous cystadenoma
and 86780 pmol/L in the fluid of the hydrosalpinx, re-
spectively the maximum values of HE4 in ascites ob-
served in the course of ovarian cancer were only 30 000
pmol/L, and in the liquid from a malignant epithelial
tumor only 15 068 pmol/L. We found no correlation,
neither, between the HE4 values in serum and periton-
eal fluid in the whole studied population and only in
the group of women with ovarian cancer, which may in-
dicate increased vascular permeability of the tumor.
Based on our research, the HE4 determinations in the
peritoneal fluid cannot be considered a valuable diag-
nostic method (AUC = 0.575).
In the summary of our results, it appears that the
HE4 marker high concentrations in the peritoneal
fluid are not specific to ovarian cancer patients. Most
probably, the determination of HE4 in the peritoneal
fluid as well as in the fluid from ovarian cyst/tumor
has no diagnostic value. More research is needed which
shall be aimed at the assessment of HE4 formation
whose high concentrations are detectable in most pel-
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